Natera (NTRA) Statistics

Founded in 2004, Natera Inc (NTRA) is a leading genetic testing and diagnostics company that specializes in reproductive health, oncology, and organ transplantation. The company utilizes advanced technologies, such as next-generation sequencing and single-nucleotide polymorphism (SNP) genotyping, to provide accurate and reliable genetic testing solutions. With a focus on improving patient outcomes, Natera offers a range of products and services, including non-invasive prenatal testing (NIPT), carrier screening, and liquid biopsy testing for cancer detection. These innovative solutions have positioned Natera as a trusted partner for physicians and patients worldwide.

Natera's strong financial performance is evident in its valuation metrics. As of the latest data, Natera Inc has a market capitalization of over $8 billion and a price-to-earnings (P/E) ratio of approximately -286. This negative P/E ratio reflects the company's current focus on growth and expansion rather than profitability. In terms of its fundamentals, Natera Inc recorded a revenue growth rate of 41% in the last quarter, demonstrating its ability to generate significant revenue despite the ongoing challenges in the healthcare industry. Additionally, Natera's Enterprise to EBITDA ratio stands at 33.1, indicating the company's ability to generate substantial earnings before interest, taxes, depreciation, and amortization.